ATE106250T1 - Verwendung von antikörper-antigen-wechselwirkung zum schutz oder modulation der biologischen aktivität. - Google Patents

Verwendung von antikörper-antigen-wechselwirkung zum schutz oder modulation der biologischen aktivität.

Info

Publication number
ATE106250T1
ATE106250T1 AT88305934T AT88305934T ATE106250T1 AT E106250 T1 ATE106250 T1 AT E106250T1 AT 88305934 T AT88305934 T AT 88305934T AT 88305934 T AT88305934 T AT 88305934T AT E106250 T1 ATE106250 T1 AT E106250T1
Authority
AT
Austria
Prior art keywords
antibody
biological activity
molecule
complex
inactivation
Prior art date
Application number
AT88305934T
Other languages
English (en)
Inventor
Ezekiel Y Shami
Aser Rothstein
Mohabir Ramjeesingh
Original Assignee
Hybrisens Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybrisens Ltd filed Critical Hybrisens Ltd
Application granted granted Critical
Publication of ATE106250T1 publication Critical patent/ATE106250T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82—Asparaginase (3.5.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT88305934T 1987-07-07 1988-06-30 Verwendung von antikörper-antigen-wechselwirkung zum schutz oder modulation der biologischen aktivität. ATE106250T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7186187A 1987-07-07 1987-07-07
US18253088A 1988-04-18 1988-04-18
US20574888A 1988-06-21 1988-06-21

Publications (1)

Publication Number Publication Date
ATE106250T1 true ATE106250T1 (de) 1994-06-15

Family

ID=27371979

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88305934T ATE106250T1 (de) 1987-07-07 1988-06-30 Verwendung von antikörper-antigen-wechselwirkung zum schutz oder modulation der biologischen aktivität.

Country Status (7)

Country Link
EP (1) EP0298654B1 (de)
JP (1) JPH01138461A (de)
AT (1) ATE106250T1 (de)
AU (1) AU1865288A (de)
DE (1) DE3889783T2 (de)
DK (1) DK375188A (de)
ES (1) ES2056108T3 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686579A (en) * 1988-06-21 1997-11-11 Hybrisens, Ltd. Use of antibody/antigen interactions to protect biologically active proteins and peptides
JPH03133378A (ja) * 1989-07-19 1991-06-06 Modrovich Ivan E 被験体を安定化させて液体中でのその生物学的活性を保存する方法
CA2055812A1 (en) * 1990-11-20 1992-05-21 Carl N. Skold Method of stabilizing enzyme conjugates
AU6953696A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising antibody controlled amylolytic activity
AU6849796A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising antibody controlled enzymatic activity
AU6953796A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising antibody controlled cellulolytic activity
WO1998007816A1 (en) * 1996-08-16 1998-02-26 The Procter & Gamble Company Detergent compositions comprising oxido-reductase antibody
AU6777296A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising antibody controlled lipolytic activity
AU6849696A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising antibody controlled proteolytic activity
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2561732A1 (en) * 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited Antibody drug
KR20070084069A (ko) * 2004-10-08 2007-08-24 도만티스 리미티드 Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법
EP1988920A1 (de) 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Verfahren zur behandlung von fettsucht durch verabreichung eines trkb-antagonisten

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
ES2019067B3 (es) * 1985-12-28 1991-06-01 Nippon Hypox Laboratories Incorporated Complejo de albumina.
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides

Also Published As

Publication number Publication date
DE3889783D1 (de) 1994-07-07
DK375188A (da) 1989-01-08
EP0298654A3 (en) 1990-02-07
JPH01138461A (ja) 1989-05-31
EP0298654B1 (de) 1994-06-01
EP0298654A2 (de) 1989-01-11
DK375188D0 (da) 1988-07-06
DE3889783T2 (de) 1994-09-08
ES2056108T3 (es) 1994-10-01
AU1865288A (en) 1989-01-12

Similar Documents

Publication Publication Date Title
ATE106250T1 (de) Verwendung von antikörper-antigen-wechselwirkung zum schutz oder modulation der biologischen aktivität.
DE68903558D1 (de) Verfahren zur inaktivierung von viren.
DE3584282D1 (de) Herstellung von mikrobieller zellulose.
ATE42206T1 (de) Verfahren und zusammensetzung zur gleichzeitigen reinigung und desinfektion von kontaktlinsen.
ATE5898T1 (de) Verfahren zur enzymatischen glucoseoxidation.
ATE184289T1 (de) Ribosomen-inaktivierende proteine, inaktive vorläuferformen derselben, verfahren zur herstellung und eine methode zur nutzung
ATE525390T1 (de) Verwendung von resistin spezifischen antikörpern in der behandlung von diabetes
DE3884895D1 (de) Verwendung von Bezafibrat zur Behandlung von Diabetes.
ATE129012T1 (de) Enzymatische oxidation von ceph c zu glutaryl-7- aminocephalosporansäure.
YU88092A (sh) Enzimatski postupak za enantioselektivno pripremanje optički aktivnih cijanhidrina
EP0121254A3 (en) Process for determining substrate or enzymatic activity
FI931554A0 (fi) Foerfarande foer utvinning av enzymer fraon proenzymer
ES478533A1 (es) Un procedimiento para eliminar melamina de liquidos que con-tienen melamina.
ATE54065T1 (de) Katalysatorherstellung.
DK0457035T3 (da) Fremgangsmåde til inaktivering af den biologiske aktivitet af DNA
DK710588A (da) Enzym samt fremgangsmaade til enzymatisk hydrolyse af alfa-aminoadipinyl-monoaminoforbindelser
DE3889845D1 (de) Verfahren zur Massanalyse von Wasserstoff-Peroxyd und Reagens dafür.
SE8600987L (sv) Forfarande for framstellning av ett protein- koncentrat ur helblod
ATE4326T1 (de) Verfahren zur gewinnung von cholesterinesterase.
DE69422298D1 (de) Enzym und dessen verwendung zur herstellung von (s)-pipecolinsäure
ATE273712T1 (de) Methode zur inaktivierung von proteinen der ras- unterfamilie und verbindungen dafuer
DE3775866D1 (de) Verfahren zur durchfuehrung enzymatischer oxidationen.
DK591187A (da) Fremgangsmaade til fremstilling af n-(dichlorphosphoryl)-trichlorphosphazen
ATE11568T1 (de) Verfahren zur herstellung von 11-alpha-hydroxy-20-alpha-hydroxymethyl-1,4-pre nadien-3-on.
DE3880618D1 (de) Verfahren zur verhinderung des wachstums von kleinlebewesen in waessrigen fluessigkeiten.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties